Skip to content
OpenCapital
Get started

Akebia Therapeutics AKBA Q1 2026 earnings

Reported May 7, 2026 · Before market open

Revenue$53.5MBeat by $1.9M
EPS-$0.03Miss by $0.02
Revenue estimate$51.7M
EPS estimate-$0.01

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$48.9M
EPS estimate-$0.03

Versus estimates

Revenue

Q1 2026$53.5MBeat by $1.9M
Q4 2025$57.6MBeat by $11.5MQ3 2025$58.8MBeat by $10.4MQ2 2025$62.5MBeat by $14.6MQ1 2025$57.3MBeat by $6.5MQ4 2024$46.5MBeat by $9.1M

Diluted EPS

Q1 2026-$0.03Miss by $0.02
Q4 2025-$0.05Miss by $0.02Q3 2025$0.00Beat by $0.06Q2 2025$0.00Beat by $0.02Q1 2025$0.03Beat by $0.06Q4 2024-$0.10Miss by $0.05

Ask the moment Akebia Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Akebia Therapeutics report Q1 2026 earnings?
Akebia Therapeutics (AKBA) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Akebia Therapeutics's Q1 2026 revenue and EPS?
Akebia Therapeutics reported revenue of $53.5M and eps of $-0.03 for Q1 2026.
Did Akebia Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $51.7M by $1.9M. EPS missed the consensus estimate of $-0.01 by $0.02.
How did Akebia Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 6.6% from $57.3M a year earlier.
Where can I find Akebia Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001517022-26-000038) and the 10-Q periodic report (0001517022-26-000039) directly on SEC EDGAR. The filing index links above go to sec.gov.